LUMAKRAS® is the only once-daily oral treatment for *KRAS* G12C–positive non-small cell lung cancer (NSCLC)[1]



"I'm grateful to share my story, which can help others. Helping others is always more fulfilling."

–Laurie S.
Actual LUMAKRAS® patient at time of quote

Patient story represents individual's experience with LUMAKRAS®. *Results may vary.*

LUMAKRAS® is not a chemotherapy. It is used after at least one other treatment, if the cancer has spread to other parts of the body or cannot be removed by surgery, and the tumor is *KRAS* G12C–positive.[1,2]

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

- that has spread to other parts of the body or cannot be removed by surgery, and
- whose tumor has an abnormal KRAS G12C gene, and
- who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
  - have liver problems.
  - have lung or breathing problems other than lung cancer
  - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
  - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H_2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

What is *KRAS* G12C?


"If I didn't advocate for myself, I wouldn't have had testing and I would not have found out I was *KRAS* G12C–positive."



–Laurie S.
Actual LUMAKRAS® patient at time of quote

Patient story represents individual's experience with LUMAKRAS®. *Results may vary.*

What is a biomarker?



A biomarker is a molecule found in blood, other body fluids, or tissues, that is a sign of a normal or abnormal process, or of a condition or disease[3]

There are many different molecules that are considered biomarkers[3]

Knowing your biomarker status is an important step toward targeted treatment[3]

One biomarker that is present in some cancers, including non-small cell lung cancer (NSCLC), is known as *KRAS*[1,3,4]

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

What is *KRAS*?



KRAS is a biomarker we all have in our bodies. *KRAS* acts like an on/off switch that tells cells when to grow and when to stop growing[3]

Like many biomarkers, *KRAS* can mutate. Mutations are changes that occur in DNA. DNA is your body's blueprint for its development and function[3]



One possible *KRAS* mutation in NSCLC is known as *KRAS* G12C[3]

What is a *KRAS* G12C mutation?



KRAS G12C is a mutant *KRAS* biomarker[4]

KRAS G12C causes that on/off switch to get stuck in the "on" position. This causes continuous and uncontrolled cell growth that can form tumors. Some tumors can be cancerous[5]

Approximately **1 in 8 people** with NSCLC have the *KRAS* G12C mutation[6]



How do I find out if I have a *KRAS* G12C mutation?

- Your doctor can test you for *KRAS* G12C by performing a biopsy. This is when a doctor takes a sample from your tumor or blood for testing. These are called tissue biopsies or liquid biopsies, depending on what type of sample is being examined[3]
- Your doctor will help determine which test is right for you

If you have the *KRAS* G12C mutation, there is a treatment—LUMAKRAS®—**designed for your type of lung cancer** if you have already received at least one treatment[1]

To find out if you have *KRAS* G12C, ask your doctor for a biomarker test. Make sure your results are available whenever you're discussing your treatment plan with your doctor[1,3]

Important Safety Information (Continued)

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

What is LUMAKRAS®?

How does LUMAKRAS® work to treat NSCLC?



Tumors with the *KRAS* G12C mutation remain stuck in the "on" position. This causes cells to grow without stopping[3,5]

LUMAKRAS® targets the *KRAS* G12C mutation and locks it in the "off" position. This may help prevent tumor cell growth[1]



How did LUMAKRAS® work in the trial?

In a clinical trial, 126 adults with *KRAS* G12C–mutated NSCLC were given an oral treatment called LUMAKRAS®. The trial evaluated how many adults with NSCLC responded to LUMAKRAS®, meaning their tumors either shrank or disappeared from the initial scan. The trial also measured how long the tumor responded to LUMAKRAS®[1]

More than 1 in 3 people taking LUMAKRAS® saw their tumor shrink[1,*]

36% **of people saw their tumor shrink* or disappear[1]**



was the median time a patient's tumor did not grow or spread to other parts of the body[1]

*At least 30%.[7]

These results were based on 45 people, of which 2 people saw their tumor completely disappear, and 43 people saw their tumor partially shrink[1,7]

Important Considerations: The approval of LUMAKRAS® in these patients is based on a study that measured the size of tumor shrinkage.[1]

LUMAKRAS® is the first medicine for *KRAS* G12C cancer to be studied, and it was tested in the largest *KRAS* G12C study to date. Talk to your doctor to see if LUMAKRAS® is right for you[8]

Important Safety Information (Continued)

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
  - have liver problems.
  - have lung or breathing problems other than lung cancer.
  - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
  - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.

What are the possible side effects of LUMAKRAS®?

When taking any medication, it's important to be aware of any side effects that you may experience. Talk to your doctor immediately if you notice any side effects so they can make an appropriate decision about further treatment[2]

LUMAKRAS® may cause serious side effects, including:[2]

- **Liver problems:** LUMAKRAS® may cause abnormal liver blood test results. Your doctor should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function
  - Tell your doctor right away if you get any signs or symptoms of liver problems. These may include: your skin or the white part of your eyes turn yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen)
- **Lung or breathing problems:** LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your health care provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever

If you experience any of these side effects while taking LUMAKRAS®, you should call your doctor right away[2]

The most common side effects of LUMAKRAS® include:[2]

- Diarrhea
- Nausea
- Cough
- Muscle or bone pain
- Tiredness
- Changes in certain blood tests

These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN)[2]

Important Safety Information (Continued)

- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H_2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

How do I take LUMAKRAS®?

How to take LUMAKRAS®

Take your prescribed dose of LUMAKRAS®:

- **Once daily by mouth[2]**
- **At the same time every day[2]**
- **With or without food[2]**

Your doctor will decide how much LUMAKRAS® you need. A typical dose is 960 mg[2]

- Take LUMAKRAS® exactly as your doctor tells you to take it. Do not change your dose or stop taking LUMAKRAS® **unless your doctor tells you to[2]**
- Take the number of tablets (pills) your doctor prescribes. **If you have a side effect, talk to your doctor[2]**

LUMAKRAS® is the only once-daily oral therapy for *KRAS* G12C–positive NSCLC

Important things to remember when taking LUMAKRAS®

If you take an **antacid medicine,** such as Tums®, take LUMAKRAS® either 4 hours before or 10 hours after the antacid. Speak to your doctor if you are on a proton pump inhibitor like Prilosec®, or an H_2 blocker like Pepcid AC®[2]

If you **miss a dose** of LUMAKRAS®, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose[2]

If you **vomit after taking a dose** of LUMAKRAS®, do not take an extra dose. Take your next dose at your regularly scheduled time the next day[2]

LUMAKRAS® recommended once-daily, starting dosage: 960 mg orally[1]

x4 **240 mg tablets once daily[1]**

Tablet as seen may not reflect actual size.

LUMAKRAS® 240 mg tablets have a yellow color. They come in one bottle containing 120 tablets.



Please make sure you take the right number of tablets.[1] LUMAKRAS® tablets are comparable in size to a dime.[9] Speak with your doctor if you have any questions or if you experience a side effect.

If you have a side effect, your doctor may change your dose, temporarily stop, or permanently stop you from taking LUMAKRAS®[2]

When taking your daily dose of LUMAKRAS®:

- Swallow LUMAKRAS® tablets whole. **Do not chew, crush, or split tablets[2]**

If you cannot swallow LUMAKRAS® tablets whole:[2]

1. Place your prescribed dose of LUMAKRAS® in a glass of 4 ounces (120 mL) of non-carbonated, room temperature water. Do not crush the tablets. Do not use liquids other than water
2. Stir or swirl the cup for about **3 minutes** until the tablets have broken down into small pieces. **They will not completely dissolve.** Drink immediately or within 2 hours. The appearance of the mixture may range from pale yellow to bright yellow
3. Swallow the broken-down tablet mixture. Do not chew pieces of the tablet
4. Rinse the glass with an additional 4 ounces (120 mL) of water and drink
5. If the mixture is not consumed immediately, stir or swirl the mixture again to ensure the tablets are mixed into the water and drink

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

Support from Amgen

“I’m thankful to everybody. You know, all my family, the doctors. Anybody involved that have helped me through this journey—I’m very appreciative.”

Patient story represents individual's experience with LUMAKRAS®. *Results may vary.*



AMGEN® Support+

We're right here, right when you need us

Personalized patient support designed for you. With financial resources and other helpful patient support services, we are here to help you along the way.

Call Amgen SupportPlus at 866-264-2778

Monday – Friday 9:00 AM – 8:00 PM ET.

Visit AmgenSupportPlus.com to learn how Amgen can help.

Amgen® Nurse Partners

Amgen Nurse Partners will be with you along the way to offer support and provide information about resources to help you access your prescribed Amgen medication.

Amgen Nurse Partners can provide support, including:

- Guidance on resources that may help lower out-of-pocket medication costs
- Assistance to help you stay on track with your medication
- Answers to your questions about Amgen SupportPlus

Get connected with an Amgen Nurse Partner* by enrolling in Amgen SupportPlus:

- **Download and complete the Amgen SupportPlus Enrollment Form found on AmgenSupportPlus.com and fax to 1-866-218-4777**
- **Call 1-866-264-2778 to enroll by phone**

*Amgen Nurse Partners are only available to patients who are prescribed certain products. Nurse Partners are there to support, not replace, your treatment plan, and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

If you need help paying for LUMAKRAS®

Financial Support

We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of your current financial situation or type of insurance you have.

AMGEN® Support+ | Co-Pay Program

If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible to pay as little as $0 for your prescription.

The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs

- Pay as little as $0† out-of-pocket for each dose
- Can be applied to deductible, co-insurance, and co-payment†
- No income eligibility requirement



What if I don’t have commercial or private insurance (ie, self-purchased or through an employer)?

Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help.‡

Learn more about available options from Amgen SupportPlus

†Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

How can I learn more?

“Be your own biggest advocate. Every time I meet with my doctor, I bring a list of questions.”



–Laurie S.
Actual LUMAKRAS® patient at time of quote

Patient story represents individual's experience with LUMAKRAS®. *Results may vary.*

Where can I get LUMAKRAS®?

There are multiple ways to receive your LUMAKRAS®. Talk to your doctor about your options

- LUMAKRAS® may be available through a specialty pharmacy. Specialty pharmacies provide medicines for rare or complex illnesses. Your doctor can help you find a specialty pharmacy that works with your insurance
- **Working with a specialty pharmacy:** Once your insurance coverage has been verified, the specialty pharmacy will contact you to set up delivery of your prescription
- Specialty pharmacy providers may be able to help you with the following:

Fill your prescription and coordinate home delivery

Help you navigate your insurance coverage

Connect you to additional support services

Answer questions about paying for your treatment

How can I connect with others with NSCLC?

There are many lung cancer organizations and patient communities that can provide you with useful information and offer you and your caregiver much-needed support. We've included a few examples of independent, nonprofit organizations that may be able to help people with NSCLC

LUNGEVITY Transforming Lung Cancer
www.lungevity.org

GO2 FOR LUNG CANCER
www.go2.org

CANCER SUPPORT COMMUNITY
COMMUNITY IS STRONGER THAN CANCER
www.cancersupportcommunity.org

KRAS KICKERS
KRASKICKERS.ORG
www.kraskickers.org

These websites are being shared for informational purposes only; they do not constitute an endorsement by Amgen of any products, services, or opinions of the organization or individual. Amgen bears no responsibility for the accuracy, legality, or content of these external sites. The advocacy organizations don't endorse any specific cancer treatments. Talk with your doctor about what treatment is right for you.

How can I prepare to talk to my doctor about NSCLC and *KRAS* G12C?

Sometimes it’s challenging to discuss all of your questions and concerns in one doctor visit. Here are some considerations to help organize your thoughts*

Before your appointment:

- Write down things you want to discuss. Put the most important topics at the top so you get to them first
- Think about bringing a friend or loved one with you, or have them present if you are doing a video call
- Here are some topics that may be helpful to ask your doctor about:
  - What is my biomarker status?
  - Why am I being put on treatment?
  - How does the treatment work?
  - What should I expect from treatment?

During your appointment:

- You may want to ask about your biomarker status
  - If you don’t know whether or not you’ve had a biomarker test, talk to your doctor
  - If you have had a biomarker test, ask your doctor for the results
  - You may want to keep those results somewhere safe for future appointments. They could be helpful at visits when you talk about treatment

After your appointment:

- If you change doctors, make sure you share the results of your biomarker test with your new doctor
- Think about organizing information on biomarker testing and treatment in an easy-to-access location

*Amgen cannot make any clinical recommendations or render medical or nursing advice, treatment, opinions, or care. The above is not intended to be a source of medical advice or treatment and does not, in any way, replace independent medical advice regarding your diagnosis or treatment.

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

Please see additional Important Safety Information throughout this brochure and full Important Safety Information on page 12.

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
  - have liver problems.
  - have lung or breathing problems other than lung cancer
  - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
  - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H_2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

- Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

Please see LUMAKRAS® full Patient Information.

References: 1. LUMAKRAS® (sotorasib) prescribing information, Amgen. **2.** LUMAKRAS® (sotorasib) patient information, Amgen. **3.** NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed November 21, 2025. **4.** Ryan MB, et al. *Nat Rev Clin Oncol.* 2018;15:709-711. **5.** Hong DS, et al. *N Engl J Med.* 2020;383:1207-1217. **6.** Data on file, Amgen; [Analysis of AACR Genie]. **7.** Sotorasib CSR. Amgen; 2021. **8.** Data on file, Amgen; [Trial Sites]. **9.** Data on file, Amgen; [Sotorasib Tablet Size].

AMGEN

LUMAKRAS® is a trademark of Amgen Inc.
© 2025 Amgen Inc. All rights reserved.
USA-510-82009 12/25

ONCE-DAILY ORAL
LUMAKRAS®
(sotorasib) 240 mg tablets